Background: Inflammatory bowel disease (IBD) is a chronic relapsing and remitting inflammation of the bowel. Biologic therapy is safe and effective in IBD. Anti-TNF agents were the first biologics introduced for treatment of IBD. As more and more anti-TNF agents joined the market, treating physicians started using ant-TNF agents consecutively when the first agent failed. Data for this treatment choice is scanty and therefore we set out to evaluate tandem use of anti-TNF agents in IBD patients.Method: The South African Gastroenterology Society (SAGES) established a national database for all IBD patients commenced on biologic therapy. We used this registry to evaluate the data for all patients who received consecutive anti-TNF agents. Demographic and clinical details as well as treatment outcomes for all patients were documented. Results: Eight-seven (7.6%) of 1150 patients received consecutive anti-TNF agents. The Crohn’s disease (CD) group had 42 (48%) patients and ulcerative colitis (UC) group 45 (52%). Gender distribution was equal with 45 (52%) male and 42 (48%) female patients. All patients failed the first anti-TNF agent over time, but better remission rates were obtained with consecutive anti-TNF agents. Patients treated with adalimumab during any stage of the study, had a higher rate of dose escalation compared to infliximab prior to switching to next anti-TNF agent. Similarly, side effects were also more significant with adalimumab, although few. Few patients required a switch to a third and further biologic agent. All patients remained in clinical remission over 4 years of the study.Conclusion: It is reasonable to try a second anti-TNF agent when the first agent failed in IBD. Switching between different anti-TNF agents maintained clinical remission and avoided surgery and hospitalisation. This is a cost-effective strategy especially in resource constraint settings. Adalimumab is associated with higher rates of dose escalation and worse side-effect profile
Background: Inflammatory bowel disease is a chronic relapsing and remitting inflammation of the bowel. Tumour necrosis factor α - antagonists are safe and effective in the treatment of IBD. Indications and outcomes with consecutive anti-TNF agent, although often used, are not clear. Since data for this treatment choice is scarce, we set out to evaluate the use of consecutive anti-TNF agents in patients with IBD.Method: A national registry established by The South African Gastroenterology Society was used for retrospective data extraction in patients with consecutive anti-TNF agent use. Demographic, clinical details, treatment outcomes and adverse events were documented. Results: Eight-six (7.5%) of 1150 patients received consecutive TNFα-antagonists. There were 41 (48%) patients with Crohn’s disease and 45 (52%) with ulcerative colitis. Gender distribution was equal with 45 (52%) male and 41 (48%) female patients. Patients failed the first anti-TNF over 30 months, but remission rates improved with second agent. Immunomodulator therapy had no effect of anti-TNF discontinuation rates. Adalimumab treatment had higher rate of dose escalation/switching as well as adverse events compared to infliximab. Most patients remained in clinical remission except a few with CD who required surgery.Conclusion: Using a second anti-TNF agent when the first agent failed is often necessary in IBD. Although cost-effective, this strategy lacks clarity. Patient selection is crucial and therapeutic drug monitoring should be central in that decision. Adalimumab is associated with higher rates of dose escalation and a worse side-effect profile. Patients with UC switched earlier compared to CD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.